Timothy E Sweeney1,2, James L Wynn3, María Cernada4, Eva Serna5, Hector R Wong6,7, Henry V Baker8, Máximo Vento4, Purvesh Khatri1,2. 1. Institute for Immunity, Transplantation, and Infections, Stanford University, California. 2. Division of Biomedical Informatics, Department of Medicine, Stanford University, California. 3. Departments of Pediatrics and Pathology, Immunology and Experimental Medicine, University of Florida College of Medicine, Gainesville. 4. Health Research Institute, Division of Neonatology, University and Polytechnic Hospital La Fe, Valencia, Spain. 5. Central Research Unit-INCLIVA, Faculty of Medicine, University of Valencia, Spain. 6. Cincinnati Children's Hospital Medical Center, Ohio. 7. Cincinnati Children's Research Foundation, Department of Pediatrics, University of Cincinnati College of Medicine, Ohio. 8. Department of Molecular Genetics and Microbiology, University of Florida College of Medicine, Gainesville.
Abstract
WHAT’S KNOWN ON THIS SUBJECT: Neonates are at increased risk for developing sepsis, but this population often exhibits ambiguous clinical signs that complicate the diagnosis of infection. No biomarker has yet shown enough diagnostic accuracy to rule out sepsis at the time of clinical suspicion. WHAT THIS STUDY ADDS: We show that a gene-expression-based signature is an accurate objective measure of the risk of sepsis in a neonate or preterm infant, and it substantially improves diagnostic accuracy over that of commonly used laboratory-based testing. Implementation might decrease inappropriate antibiotic use. BACKGROUND: Neonatal sepsis can have devastating consequences, but accurate diagnosis is difficult. As a result, up to 200 neonates with suspected sepsis are treated with empiric antibiotics for every 1 case of microbiologically confirmed sepsis. These unnecessary antibiotics enhance bacterial antibiotic resistance, increase economic costs, and alter gut microbiota composition. We recently reported an 11-gene diagnostic test for sepsis (Sepsis MetaScore) based on host whole-blood gene expression in children and adults, but this test has not been evaluated in neonates. METHODS: We identified existing gene expression microarray-based cohorts of neonates with sepsis. We then tested the accuracy of the Sepsis MetaScore both alone and in combination with standard diagnostic laboratory tests in diagnosing sepsis. RESULTS: We found 3 cohorts with a total of 213 samples from control neonates and neonates with sepsis. The Sepsis MetaScore had an area under the receiver operating characteristic curve of 0.92-0.93 in all 3 cohorts. We also found that, as a diagnostic test for sepsis, it outperformed standard laboratory measurements alone and, when used in combination with another test(s), resulted in a significant net reclassification index (0.3-0.69) in 5 of 6 comparisons. The mean point estimates for sensitivity and specificity were 95% and 60%, respectively, which, if confirmed prospectively and applied in a high-risk cohort, could reduce inappropriate antibiotic usage substantially. CONCLUSIONS: The Sepsis MetaScore had excellent diagnostic accuracy across 3 separate cohorts of neonates from 3 different countries. Further prospective targeted study will be needed before clinical application.
WHAT’S KNOWN ON THIS SUBJECT: Neonates are at increased risk for developing sepsis, but this population often exhibits ambiguous clinical signs that complicate the diagnosis of infection. No biomarker has yet shown enough diagnostic accuracy to rule out sepsis at the time of clinical suspicion. WHAT THIS STUDY ADDS: We show that a gene-expression-based signature is an accurate objective measure of the risk of sepsis in a neonate or preterm infant, and it substantially improves diagnostic accuracy over that of commonly used laboratory-based testing. Implementation might decrease inappropriate antibiotic use. BACKGROUND: Neonatal sepsis can have devastating consequences, but accurate diagnosis is difficult. As a result, up to 200 neonates with suspected sepsis are treated with empiric antibiotics for every 1 case of microbiologically confirmed sepsis. These unnecessary antibiotics enhance bacterial antibiotic resistance, increase economic costs, and alter gut microbiota composition. We recently reported an 11-gene diagnostic test for sepsis (Sepsis MetaScore) based on host whole-blood gene expression in children and adults, but this test has not been evaluated in neonates. METHODS: We identified existing gene expression microarray-based cohorts of neonates with sepsis. We then tested the accuracy of the Sepsis MetaScore both alone and in combination with standard diagnostic laboratory tests in diagnosing sepsis. RESULTS: We found 3 cohorts with a total of 213 samples from control neonates and neonates with sepsis. The Sepsis MetaScore had an area under the receiver operating characteristic curve of 0.92-0.93 in all 3 cohorts. We also found that, as a diagnostic test for sepsis, it outperformed standard laboratory measurements alone and, when used in combination with another test(s), resulted in a significant net reclassification index (0.3-0.69) in 5 of 6 comparisons. The mean point estimates for sensitivity and specificity were 95% and 60%, respectively, which, if confirmed prospectively and applied in a high-risk cohort, could reduce inappropriate antibiotic usage substantially. CONCLUSIONS: The Sepsis MetaScore had excellent diagnostic accuracy across 3 separate cohorts of neonates from 3 different countries. Further prospective targeted study will be needed before clinical application.
Authors: Barbara J Stoll; Nellie I Hansen; Pablo J Sánchez; Roger G Faix; Brenda B Poindexter; Krisa P Van Meurs; Matthew J Bizzarro; Ronald N Goldberg; Ivan D Frantz; Ellen C Hale; Seetha Shankaran; Kathleen Kennedy; Waldemar A Carlo; Kristi L Watterberg; Edward F Bell; Michele C Walsh; Kurt Schibler; Abbot R Laptook; Andi L Shane; Stephanie J Schrag; Abhik Das; Rosemary D Higgins Journal: Pediatrics Date: 2011-04-25 Impact factor: 7.124
Authors: James L Wynn; Scott O Guthrie; Hector R Wong; Patrick Lahni; Ricardo Ungaro; M Cecilia Lopez; Henry V Baker; Lyle L Moldawer Journal: Mol Med Date: 2015-06-02 Impact factor: 6.354
Authors: Leming Shi; Wendell D Jones; Roderick V Jensen; Stephen C Harris; Roger G Perkins; Federico M Goodsaid; Lei Guo; Lisa J Croner; Cecilie Boysen; Hong Fang; Feng Qian; Shashi Amur; Wenjun Bao; Catalin C Barbacioru; Vincent Bertholet; Xiaoxi Megan Cao; Tzu-Ming Chu; Patrick J Collins; Xiao-Hui Fan; Felix W Frueh; James C Fuscoe; Xu Guo; Jing Han; Damir Herman; Huixiao Hong; Ernest S Kawasaki; Quan-Zhen Li; Yuling Luo; Yunqing Ma; Nan Mei; Ron L Peterson; Raj K Puri; Richard Shippy; Zhenqiang Su; Yongming Andrew Sun; Hongmei Sun; Brett Thorn; Yaron Turpaz; Charles Wang; Sue Jane Wang; Janet A Warrington; James C Willey; Jie Wu; Qian Xie; Liang Zhang; Lu Zhang; Sheng Zhong; Russell D Wolfinger; Weida Tong Journal: BMC Bioinformatics Date: 2008-08-12 Impact factor: 3.169
Authors: Claire L Smith; Paul Dickinson; Thorsten Forster; Marie Craigon; Alan Ross; Mizanur R Khondoker; Rebecca France; Alasdair Ivens; David J Lynn; Judith Orme; Allan Jackson; Paul Lacaze; Katie L Flanagan; Benjamin J Stenson; Peter Ghazal Journal: Nat Commun Date: 2014-08-14 Impact factor: 14.919
Authors: James Ducharme; Wesley H Self; Tiffany M Osborn; Nathan A Ledeboer; Jonathan Romanowsky; Timothy E Sweeney; Oliver Liesenfeld; Richard E Rothman Journal: J Pers Med Date: 2020-12-07
Authors: Fleur M Keij; Niek B Achten; Gerdien A Tramper-Stranders; Karel Allegaert; Annemarie M C van Rossum; Irwin K M Reiss; René F Kornelisse Journal: Front Pediatr Date: 2021-04-01 Impact factor: 3.418
Authors: Steven L Raymond; Russell B Hawkins; Zhongkai Wang; Juan C Mira; Julie A Stortz; Feifei Han; Jennifer D Lanz; Laura V Hennessy; Babette A Brumback; Henry V Baker; Philip A Efron; Scott C Brakenridge; Wenzhong Xiao; Ronald G Tompkins; Joseph Cuschieri; Frederick A Moore; Ronald V Maier; Lyle L Moldawer Journal: Ann Surg Date: 2020-05 Impact factor: 13.787